ProPhase Labs
Operator of whole-genome sequencing, esophageal diagnostics, and OTC supplement brands.
Something off on this page? Send us feedback.
Profile
ProPhase Labs combines consumer genomics, BE-Smart esophageal cancer diagnostics, biopharma assets, and OTC supplements. Recent company updates also center on recovering unpaid COVID-era laboratory testing claims, while its operating base depends on commercialization partners, collections, and regulated clinical testing workflows.
ProPhase Labs is a healthcare company organized around consumer products and diagnostic services, with current emphasis on Nebula Genomics and DNA Complete whole-genome sequencing, BE-Smart esophageal cancer risk testing, ProPhase BioPharma compounds, and TK Supplements. Its products are primarily developed, marketed, or serviced from the United States, while the consumer genomics offering is sold online and can serve customers outside the country through digital reports and subscriptions.
The company has shifted away from broad COVID testing operations and is pursuing recovery of unpaid or underpaid testing claims through Crown Medical Collections. Management has also started a sale or partnership process for BE-Smart to reach clinical distribution without carrying the full commercialization burden internally. The business depends on clinical validation, CLIA and laboratory-developed-test requirements, privacy handling for genetic data, partner distribution, and the timing of collections.
Company facts
Key statistics
Year to date −94.1% · Average volume (30d) 210.0K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026Q2 FY26 | — | −$0.22 | — | — | $1.0M | — | −6.81% |
| Jul 1, 2026Q1 FY26 | — | — | — | — | $478.0K | — | −2.50% |
| Jun 30, 2026Q1 FY26 | — | −$0.43 | — | — | $478.0K | — | −13.04% |
| Jun 24, 2026Q1 FY26 | −$1.20 | −$0.87 | +27.5% | $9.7M | $784.0K | −91.9% | −4.61% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.2M | $883.0K | $784.0K | $478.0K | $1.0M | |
| Gross profit | $526.0K | $734.0K | −$123.0K | $247.0K | $167.0K | $226.0K | |
| Operating income | −$3.7M | −$3.9M | −$4.8M | −$5.7M | −$2.6M | −$2.6M | |
| Net income | $4.0M | −$4.5M | −$6.8M | −$7.4M | −$5.4M | −$3.1M | |
| Diluted EPS | $2.10 | −$1.10 | −$1.60 | −$0.87 | −$0.43 | −$0.22 | |
| Gross margin | 36.8% | 58.9% | -13.9% | 31.5% | 34.9% | 22.4% | |
| Operating margin | -256.0% | -312.3% | -539.5% | -730.4% | -545.0% | -261.6% |
Fiscal years (4-quarter sums)FY21 $79.0M · FY22 $122.6M · FY23 $44.4M · FY24 $6.8M · FY25 $4.3M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $20.0K · Total debt $9.1M · Total assets $57.4M · Shareholders' equity −$3.1M
Dividends
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| May 24, 2022 | May 25 | Jun 3 | $3.00 | |
| Feb 28, 2022 | Mar 1 | Mar 10 | $3.00 |
Ownership
Shares outstanding 14.02M · Float 13.68M · 97.6% free float
Insiders — no current Form 4 position.
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
Not reported.